Shire PLC (LON:SHP)‘s stock had its “overweight” rating reiterated by Jefferies Group in a report released on Wednesday. They presently have a GBX 6,300 ($76.78) price objective on the biopharmaceutical company’s stock. Jefferies Group’s target price suggests a potential upside of 22.43% from the company’s current price.

Several other research analysts have also recently weighed in on the stock. Royal Bank Of Canada restated an “outperform” rating on shares of Shire PLC in a report on Friday, July 22nd. JPMorgan Chase & Co. restated an “overweight” rating and set a GBX 6,300 ($76.78) price target on shares of Shire PLC in a report on Tuesday, August 16th. Citigroup Inc. restated a “buy” rating on shares of Shire PLC in a report on Wednesday, August 3rd. Credit Suisse Group AG boosted their price target on shares of Shire PLC from GBX 5,000 ($60.94) to GBX 5,200 ($63.38) and gave the stock an “outperform” rating in a report on Wednesday, August 3rd. Finally, Deutsche Bank AG restated a “buy” rating and set a GBX 6,000 ($73.13) price target on shares of Shire PLC in a report on Wednesday, July 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eighteen have given a buy rating to the company’s stock. Shire PLC currently has an average rating of “Buy” and a consensus target price of GBX 5,888.75 ($71.77).

Analyst Recommendations for Shire PLC (LON:SHP)

Shire PLC (LON:SHP) opened at 5144.00 on Wednesday. The company’s market capitalization is GBX 35.12 billion. The stock’s 50 day moving average is GBX 5,022.47 and its 200 day moving average is GBX 4,625.73. Shire PLC has a one year low of GBX 2,707.19 and a one year high of GBX 5,377.00.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

The company also recently announced a dividend, which was paid on Friday, October 7th. Investors of record on Thursday, September 8th were issued a dividend of GBX 3.51 ($0.04) per share. This represents a yield of 0.07%. The ex-dividend date was Thursday, September 8th.

In other news, insider Dominic Blakemore bought 133 shares of the firm’s stock in a transaction that occurred on Friday, September 30th. The shares were acquired at an average price of GBX 5,010 ($61.06) per share, with a total value of £6,663.30 ($8,121.02).

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with's FREE daily email newsletter.